Immunotherapy of malignant melanoma

Surgical Clinics of North America

Volumn 76, Issue 6, 1996, Pages 1355-1381

  Leong, S P L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CISPLATIN; CYTOKINE; DACARBAZINE; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; REVIEW; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030466061     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70520-X     Document Type: Article

References (165)

1. P. Aebersold C. Hyatt S. Johnson Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response J Natl Cancer Inst 83 1991 932
2. S.S. Ahn R.F. Irie T.H. Weisenburger Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: Correlation with clinical response Surgery 92 1982 362
3. C.M. Balch A.C. Buzaid Editorial J Clin Oncol 14 1996 1
4. S. Baron S.K. Tyring W.R. Fleischmann Jr The interferons JAMA 266 1991 1375
5. P.H. Basse U. Nannmark B.R. Johansson Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells J Natl Cancer Inst 83 1991 944
6. D. Berd H.C. Maguire Jr M.J. Mastrangelo Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide Cancer Res 46 1986 2572
7. D. Berd H.C. Maguire Jr M.J. Mastrangelo Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide Cancer Res 44 1984 5439
8. D. Berd H.C. Maguire Jr P. McCue Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients J Clin Oncol 8 1990 1858
9. D. Berd M.J. Mastrangelo Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide Cancer Invest 6 1988 337
10. S. Blair L. Flaherty M. Valdivieso Comparison of high dose interleukin-2 (HD IL-2) with combined chemotherapy/low dose IL-2 (CHEMO/IL-2) in metastatic malignant melanoma (MMM) [abstract 1031] Proc Am Soc Clin Oncol 10 1991 294
11. T. Boon P. Coulie M. Marchand Genes coding for tumor rejection agents: Perspectives for specific immunotherapy Biol Ther Cancer Updates 4 1994 1
12. S. Breier R. Pensel C. Roffe High dose DTIC with recombinant human interferon alpha 2 b (rhIFN2b) for the treatment of metastatic malignant melanoma (MMM) [abstract 1090] Proc Am Soc Clin Oncol 9 1990 281
13. H.A. Briele C.W. Beattie S.G. Ronon Late recurrence of cutaneous melanoma Arch Surg 118 1983 800
14. J.P. Brown R.G. Woodbury C.E. Hart Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissue Proc Natl Acad Sci 78 1981 539
15. S.L. Brown R.A. Miller S.J. Horning Treatment of B cell lymphoma with anti-idiotype antibodies alone and in combination with alpha interferon Blood 3 1989 651
16. M. Burnet Immunologic aspects of malignant disease Lancet 1 1967 1171
17. N. Cascinelli Evaluation of efficacy of adjuvant rIFNa 2A in melanoma patients with regional node metastases [abstract] Proc Am Soc Clin Oncol 14 1995 410
18. N. Cascinelli R. Bufalino A. Morabito Results of adjuvant interferon study in WHO melanoma programme Lancet 343 1994 913
19. A.E. Chang H. Yoshizawa K. Sakai Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro Cancer Res 53 1993 1043
20. Q. Chen V. Daniel D.W. Maher P. Hersey Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma Int J Cancer 56 1994 755
21. D2specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma J Clin Oncol 5 1987 1430
22. P.A. Cohen Role of T cell subsets in tumor immunity Biol Ther Cancer Updates 4 2 1984 2 12
23. E.T. Cregan D.J. Schaid D.L. Ahmann Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders Am J Clin Oncol 11 1988 652
24. N.J. Crowley T.L. Darrow M.A. Quinn-Allen MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele J Immunol 146 1991 1692
25. D. Cupissol B. Guillot A. Stoebner Adjuvant therapy with interferon (IFN) alfa-2b on malignant melanoma patients after surgical excision of skin or lymph node recurrence: New evaluation [abstract 1048] Proc Am Soc Clin Oncol 10 1991 299
26. T.L. Darrow C.L. Slingluff H.F. Seigler The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes J Immunol 142 1989 3329
27. R.O. Dillman R.K. Oldham N.M. Barth Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial Cancer 68 1991 1
28. R.O. Dillman R.K. Oldham N.M. Barth Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: A national biotherapy study group trial J Natl Cancer Inst 82 1990 1345
29. C.A. Dinarello Biology of interleukin 1 FASEB J 2 1988 108
30. J.R. Durant Immunotherapy of cancer: The end of the beginning? N Engl J Med 316 1987 939
31. S.K. Durum J.A. Schmidt J.J. Oppenheim Interleukin 1: An immunological perspective Ann Rev Immunol 3 1985 263
32. T. Everson W. Cole Spontaneous Regression of Cancer 1966 WB Saunders Philadelphia 164
33. C.I. Falkson G. Falkson H.C. Falkson Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma J Clin Oncol 9 1991 1403
34. L.E. Flaherty B.G. Redman G.G. Chabot A phase I–II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma Cancer 65 1990 2471
35. K.H. Grabstein J. Eisenman K. Shanebeck Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor Science 264 1994 965
36. E.A. Grimm A. Mazumder H.Z. Zhang Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes J Exp Med 155 1982 1823
37. C.M. Grin-Jorgensen D.S. Rigel R.J. Friedman The worldwide incidence of malignant melanoma C.M. Balch A.N. Houghton G.W. Milton Cutaneous Melanoma 1992 JB Lippincott Philadelphia 27
38. P. Grohn E. Kumpulainen L. Nuortio A phase II study of metastatic melanoma treated with a combination of interferon alfa 2b, dacarbazine and nimustine Eur J Cancer 28 1992 441
39. J.U. Gutterman G.M. Mavligit J. Gottlieb Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxommide and bacillus Calmette Guérin N Engl J Med 291 1974 592
40. J.U. Gutterman G.M. Mavligit C.M. McBride Active immunotherapy with BCG for recurrent malignant melanoma Lancet 1 1973 1208
41. T.J. Hamblin B. Davies S. Sadullah A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cis-platin, interleukin-2 (IL-2) and alfa-interferon (IFN) [abstract 1029] Proc Am Soc Clin Oncol 10 1991 294
42. P. Hersey C. Bindon A. Edwards Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin-2 Int J Cancer 28 1981 695
43. P. Hersey G.R. McLeod D.B. Thomson Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: Long-term follow-up of two phase II studies Br J Haematol 79 Suppl 1 1991 60
44. E.M. Hersh M.A. Chirigos M.J. Mastrangelo Augmenting Agents in Cancer Treatment 1981 Raven Press New York
45. E.M. Hersh B.S. Metch F.M. Muggia Phase II studies of recombinant human tumor necrosis factor alpha (rhuTNFa) in patients with malignant disease J Immunother 10 1991 426
46. E.M. Hersh Y.Z. Patt J.U. Gutterman Hose defense mechanisms in cancer and their modification by imunotherapy Crispen Neoplasm Immunity: Experimental and Clinical 1980 Elsevier/North Holland Biomedical Press Amsterdam 247 264
47. E.M. Hersh J.R. Quesada S.G. Murphy An evaluation of therapy with the methanol extraction residue of BCG (MER) Cancer Immunol Immunother 14 1982 4
48. A.N. Houghton H. Brooks R.J. Cote Detection of cell surface and intracellular antigens by human monoclonal antibodies: Hybrid cell lines derived from lymphocytes of patients with malignant melanoma J Exp Med 158 1985 53
49. M. Howard A. O'Garra Biological properties of interleukin 10 Immunol Today 13 6 1992 198
50. J. Hu-Li E.M. Shevach J. Mizuguchi B cell stimulatory factor 1 (interleukin 4) is a potent costimulant for normal resting T lymphocytes J Exp Med 165 1987 1577
51. M.J. Humphries K. Olden K.M. Yamada A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells Science 233 1986 467
52. P. Hwu The gene therapy of cancer Cancer Principles Pract Oncol Updates 9 5 1995 1
53. K. Imai Ng A.-K. S. Ferrone Characterization of monoclonal antibodies to human melanoma-associated antigens J Natl Cancer Inst 66 1981 489
54. Interleukin-2: Sunrise for immunotherapy Lancet I 1989 308
55. R.F. Irie D.L. Morton Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2 Proc Natl Acad Sci USA 83 1986 8694
56. M. Ishihara K. Hashimoto F.M. DiGregorio Monoclonal anti-melanoma antibodies IKH-1 and IKH-2 which work on formalin-fixed, paraffin embedded tissues: Characterization, clinical trials and comparative studies with HMB-45 J Dermatol Sci 3 1991 13
57. F. Jotereau M.C. Pandolfino D. Boudart High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy J Immunother 10 1991 405
58. M. Kahn H. Sugawara P. McGowan CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen J Immunol 146 1991 3235
59. J. Kan-Mitchell A. Imam R.A. Kempf Human monoclonal antibodies directed against melanoma tumor–associated antigens Cancer Res 46 1986 2490
60. P. Kellokumpu-Lehtinen E. Nordman Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer Cancer Detect Prevent 12 1988 523
61. P. Kellokumpu-Lehtinen E. Nordman A. Toivanen Combined interferon and vinblastine treatment of advanced melanoma: Evaluation of the treatment results and the effects of the treatment on immunological functions Cancer Immunol Immunother 28 1989 213
62. J.M. Kirkwood M.S. Ernstoff The role of interferons in the management of melanoma L. Nathanson Management of Advanced Melanoma 1986 Churchill Livingstone New York 209
63. J.M. Kirkwood M.H. Strawderman M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneus melanoma: The Eastern Cooperative Oncology Group trial EST 1684 J Clin Oncol 14 1996 1
64. A. Knuth B. Danowkis H.F. Oettgen T cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin-2-dependent T cell cultures Proc Natl Acad Sci USA 81 1984 3511
65. H.K. Koh A.J. Sober H. Nakagawa Malignant melanoma and vitiligo-like leukoderma: An electron microscopic study J Am Acad Dermatol 9 1983 696
66. R.L. Kradin D.S. Lazarus S.M. Dubinett Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer Lancet 3 1989 577
67. Z. Kriazan J.L. Murray E.M. Hersh Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinants Cancer Res 45 1985 4904
68. S.M. Larson J.P. Brown P.W. Wright Imaging of melanoma with I-131–labeled monoclonal antibodies J Nucl Med 24 1983 123
69. S. Legha C. Plager S. Ring A phase II study of biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2A (IFN) in combination with cisplatin (C) vinblastine (V) and DTIC (D) in patients with metastatic melanoma [abstract 1179] Proc Am Soc Clin Oncol 11 1992 343
70. S. Legha S. Ring C. Plager Biochemotherapy using interleukin-2 (IL-2) + interferon alfa 2-A (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in advanced melanoma [abstract 1024] Proc Am Soc Clin Oncol 10 1991 293
71. S.P.L. Leong K.R. Brookenthal M. Peng Y.M. Zhou Production of interleukin-10 (IL-10) by tumor infiltrating lymphocytes (TIL) in human melanoma [abstract 3105] Proc Am Soc Clin Oncol 37 1996 455
72. S.P.L. Leong P. Enders-Zohr Y.M. Zhou Active specific immunotherapy with GM-CSF as an adjuvant to autologous melanoma (AM) vaccine in metastatic melanoma [abstract 1360] Proc Am Soc Clin Oncol 15 1996 33
73. S.P.L. Leong M.E. Granberry Y.M. Zhou Selection of cytotoxic T lymphocytes against autologous human melanoma from lymph nodes with metastatic melanoma using repeated in vitro sensitization Clin Exper Med 9 1991 301
74. S.P.L. Leong Y.M. Zhou M.E. Granberry Generation of cytotoxic effector cells against human melanoma Cancer Immunol Immunother 40 1995 397
75. D. Lienard F.J. Lejeune P. Ewalenko In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion World J Surg 16 1992 234
76. P.O. Livingston K. Kaelin C.M. Pinsky The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines Cancer 56 1985 2194
77. P.O. Livingston E.J. Natoli M.J. Claves Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients Proc Natl Acad Sci USA 84 1987 2911
78. J. Lotem Y. Shabo L. Sachs Regulation of megakaryocyte development by interleukin-6 Blood 74 1989 1545
79. M.A. Lopez-Nevot F. Esteban A. Ferron HLA class I gene expression on human primary tumours and autologous metastases: Demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas Br J Cancer 59 1989 221
80. R. Mandanas S. Schultz D. Scullin Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial Am J Clin Oncol 14 1991 397
81. K.A. Margolin A.A. Rayner M.J. Hawkins Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines J Clin Oncol 7 1989 486
82. M. Matsui M. Temponi S. Ferrone Characterization of a monoclonal antibody–defined human melanoma–associated antigen susceptible to induction by immune interferon J Immunol 139 1987 2088
83. S. Matte M.P. Colombo D. Melani Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes Int J Cancer 56 1994 853
84. G.M. Mavligit E.M. Hersh C.M. McBride Lymphocyte blastogenic responses to autochthonous viable and non-viable tumor cells J Natl Cancer Inst 51 1973 337
85. A. Mazumder S.A. Rosenberg Successful immunotherapy of natural killer–resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2 J Exp Med 159 1984 495
86. G.R.C. McLeod D.B. Thomson P. Hersey Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I–II study in combination with DTIC Int J Cancer Suppl 1 1987 31
87. O. Merimsky M. Inbar E. Shiloni Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by α-interferon and dacarbazine—a preliminary report Mol Biother 2 1990 208
88. F.L. Meyskens Jr K. Kopecky M. Samson A phase III trial of recombinant human interferon-gamma (IFN) as adjuvant therapy of high risk malignant melanoma (MM) [abstract 1019] Proc Am Soc Clin Oncol 10 1991 291
89. E. Mickiewicz R. Estevez F. Rao Interferon alfa 2b (rIFNa 2b) alone or in combination with DTIC in metastatic melanoma (MM) [abstract 1089]. Compiled data Proc Am Soc Clin Oncol 9 1990 281
90. J.W. Mier G. Vachino van der Meer J.W. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients J Clin Immunol 8 1988 426
91. M.S. Mitchell Attempts to optimize active specific immunotherapy for melanoma Int Rev Immunol 7 1991 331
92. M.S. Mitchell R.A. Kempf W. Harel Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 disseminated melanoma J Clin Oncol 6 1988 409
93. A. Mittleman Z.J. Chen H. Yang Human high molecular weight melanoma–associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proc Natl Acad Sci USA 89 1992 466
94. H. Mizoguchi J.J. O'Shea D.L. Longo Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice Science 258 1992 1795
95. C.G. Moertel T.R. Fleming J.S. Macdonald Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma N Engl J Med 322 1990 352
96. F. Momburg S. Koch Selective loss of B2-microglobulin mRNA in human colon carcinoma J Exp Med 169 1989 309
97. F. Momburg A. Ziegler J. Harprecht Selective loss of HLA-A or HLA-B antigens expression in colon carcinoma J Immunol 142 1989 352
98. Y. Morinaga H. Hidtoshi A. Takeuchi Antiproliferative effect of rh interleukin1-b (rhiL-1b) on tumor cells: Go-G. Arrest of a human melanoma cell line by IL-1 Biochem Biophys Res Comm 173 1990 186
99. B. Mukherji S.A. Wilhelm A. Guha Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression J Immunol 136 1986 1893
100. B. Mukherji S.A. Wilhelm A. Guha M.T. Ergin Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell mediated suppression of in vitro cytotoxic immune response J Immunogy 136 1986 1888
101. N.H. Mulder E.G. DeVries D.T. Sleijfer Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma Br J Cancer 65 1992 303
102. J.J. Mule J.K. McIntonsh D.M. Jablons Antitumor activity of recombinant interleukin 6 in mice J Exp Med 171 1990 629
103. J. Muraki J. Fischer J.C. Addonizio Immunosuppressive factor derived from renal cancer cells Urology 34 4 1989 205
104. P.M. Murphy H.C. Lane J.I. Gallin Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma Ann Intern Med 108 1988 36
105. 111In-labeled monoclonal antibody 96.5 Cancer Res 45 1985 2376
106. D.R. Murray W.A. Cassel A.H. Torbin Viral oncolysate in the management of malignant melanoma: II. Clinical studies Cancer 40 1977 680
107. J.L. Murray M.G. Rosenblum L. Lamki Clinical parameters related to optimal tumor localization of indium-111–labeled mouse antimelanoma monoclonal antibody ZME-018 J Nucl Med 28 1987 25
108. L.M. Muul P.J. Spiess E.P. Director Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma J Immunol 138 1987 989
109. J.B. Ochoa B. Curti A.B. Peitzman Increased circulating nitrogen oxides after human tumor immunotherapy: Correlation with toxic hemodynamic changes J Natl Cancer Inst 84 1992 864
110. H.F. Oettgen L.J. Old The history of cancer immunotherapy V.T. DeVita Jr S. Hellman S.A. Rosenberg Biologic Therapy of Cancer 1991 JB Lippincott Philadelphia 87 119
111. K. Pantel G. Schlimock D. Kutter Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells Cancer Res 51 1991 4712
112. D.R. Parkinson J.S. Abrams P.H. Wiernik Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study J Clin Oncol 8 1990 1650
113. G. Parmiani A. Anichini G. Fossati Cellular immune response against autologous human malignant melanoma: Are in vitrostudies providing a framework for a more effective immunotherapy? J Natl Cancer Inst 82 5 1990 361 361
114. C. Plager J.M. Bowen C. Fenoglio Adjuvant immunotherapy of M. D. Anderson Hospital (MDAH stage III-B malignant melanoma with Newcastle disease virus oncolysate) [abstract 1091] Proc Am Soc Clin Oncol 9 1990 281
115. L.C. Plantefaber R.O. Hynes Changes in integrin receptors on oncogenically transformed cells Cell 56 1989 281
116. R.T. Prehn J.M. Main Immunity to methylcholanthrene-induced sarcomas J Natl Cancer Inst 18 1957 769
117. J.R. Quesada M. Talpaz A. Rios Clinical toxicity of interferon in cancer patients: A review J Clin Oncol 4 1986 234
118. I.C. Quirt W.E. Shelley J.L. Pater Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: A phase III study by the National Cancer Institute of Canada clinical trials group J Clin Oncol 9 1991 729
119. B.G. Redman L. Flaherty T.H. Chou Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: Immunological effects of therapy J Immunotherapy 10 1991 147
120. D.S. Reintgen K.S. McCarty B. Woodard Metastatic malignant melanoma with an unknown primary Surg Gynecol Obstet 156 1983 335
121. J. Richards N. Mehta L. Schroeder Sequential chemotherapy/immunotherapy for metastatic melanoma [abstract 1189] Proc Am Soc Clin Oncol 11 1992 346
122. J. Richner T. Cerny R.A. Joss A phase II study of continuous subcutaneous alpha 2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma (MM) [abstract 1085] Proc Am Soc Clin Oncol 9 1990 280
123. S.A. Rosenberg Immunotherapy with recombinant cytokines and activated lymphocytes in patients with advanced cancer: Review of surgery branch, NCI experience Adj Ther Cancer 6 1990 33 38
124. S.A. Rosenberg P. Abersold K. Cornetta Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction N Engl J Med 323 1990 570
125. S.A. Rosenberg M.T. Lotze L.M. Muul A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 316 1987 889
126. S.A. Rosenberg M.T. Lotze L.M. Muul Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer N Engl J Med 313 1985 1485
127. S.A. Rosenberg M.T. Lotze J.C. Yang Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients Ann Surg 210 1989 474
128. S.A. Rosenberg B.S. Packard P.M. Aebersold Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N Engl J Med 319 1988 1676
129. M. Rosenstein S.E. Ettinghausen S.A. Rosenberg Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2 J Immunol 137 1986 1735
130. R.D. Rossen M.M. Crane A.C. Morgan Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma. A prospective study of 53 patients Cancer Res 43 1983 422
131. M.N. Saleh M.B. Khazaeli R.H. Wheeler Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma Hum Antibodies Hybridomas 3 1992 19
132. R.E.B. Seftor E.A. Seftor K.R. Gehlsen Role of the alpha v beta 3 integrin in human melanoma cell invasion Proc Natl Acad Sci USA 89 1992 1557
133. E. Severinson T. Naito H. Tokumoto Interleukin 4 (IgG1 induction factor): A multifunctional lymphokine acting also on T cells Eur J Immunol 17 1987 67
134. Y. Shabo J. Lotem M. Rubinstein The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6 Blood 72 1988 2070
135. S. Shu T. Chou S.A. Rosenberg Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy J Immunol 139 1987 295 304
136. J.P. Siegel R.K. Puri Interleukin-2 toxicity J Clin Oncol 9 1991 694
137. C.L. Slingluff Jr T. Darrow C. Vervaert Human cytotoxic T cells specific for autologous melanoma cells: Successful generation from lymph node cells in seven consecutive cases J Natl Cancer Inst 80 1988 1016
138. M.E.F. Smith S.G. Bodmer A.P. Kelly Variation in HLA expression on tumors: An escape from immune response CSH Symp Quant Biol 54 1989 581
139. J.A. Sosman P.C. Kohler J.A. Hank Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin J Natl Cancer Inst 80 1988 1451
140. L.E. Spitler A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma J Clin Oncol 9 1991 736
141. L.E. Spitler M. del Rio A. Khentigan Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin Cancer Res 47 1987 1717
142. H.F. Starnes Jr G. Hartman F. Torti Recombinant human interleukin-1b (IL-1b) has anti-tumor activity and acceptable toxicity in metastatic malignant melanoma [abstract 1023] Proc Am Soc Clin Oncol 10 1991 292
143. T.A. Steffens D.F. Bajorin A.N. Houghton Immunotherapy with monoclonal antibodies in metastatic melanoma World J Surg 16 1992 261
144. A. Steiner C. Wolf H. Pehamberger Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFNα, r-IFNγ, and r-IFNα + cimetidine) in disseminated malignant melanoma J Cancer Res Clin Oncol 113 1987 459
145. S.E. Strome J.C. Krauss A.E. Chang S. Shu Adoptive cellular immunotherapy of melanoma S.P.L. Leong Immunotherapy of Malignant Melanoma 1996 RG Landes Austin, TX 97 113
146. D. Taramelli G. Fossati A. Mazzocchi Classes I and II HLA melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions Cancer Res 46 1986 433
147. F.J. Tefany R.S. Barnetson G.M. Halliday Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma J Invest Dermatol 97 1991 197
148. M. Temponi A.M. Gold S. Ferrone Binding parameters and idiotypic profile of the whole immunoglobulin and Fab′ fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight melanoma–associated antigen Cancer Res 52 1992 2497
149. R.I. Tepper Cytokines and strategies for anticancer vaccines Contemp Oncol 12 1993 38
150. R.I. Tepper R.L. Coffman P. Leder An eosinophil-dependent mechanism for the antitumor effect of interleukin-4 Science 257 1992 548
151. N. Thatcher Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma Curr Opin Oncol 3 1991 364
152. N. Thatcher J. Wagstaff A. Mene Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma Eur J Cancer Clin Oncol 22 1986 1009
153. L. Thomas Discussion H.S. Lawrence Cellular and Humoral Aspects of the Hypersensitive States 1959 Hoever Medical Division, Harper and Row New York 529
154. D. Thomson M. Adena G.R.C. McLeod Interferon-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi-institutional Australian randomised trial QMP8704 [abstract 1177] Proc Am Soc Clin Oncol 11 1992 343
155. S.L. Topalian L.M. Mull S.A. Rosenberg Growth and immunologic characteristics of lymphocytes infiltrating human tumors Surg Forum 37 1986 390
156. D3ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites J Clin Oncol 6 1988 1636
157. Van der Bruggen P. C. Traversari P. Chomez A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma Science 254 1991 1643
158. U. Veronesi J. Adamus C. Aubert A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma N Engl J Med 307 1982 913
159. D.R. Vlock J.M. Kirkwood Serial studies of autologous antibody reactivity to melanoma: Relationship to clinical course and circulating immune complexes J Clin Invest 76 1985 849
160. S. Wadler A.I. Einzig J.P. Dutcher Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma Am J Clin Oncol 11 1988 55
161. H.J. Wanebo S.P.L. Leong Immunobiology of the cancer patient: Current concepts Toledo-Pereyra L.H. Immunology Essentials of Surgical Practice 1988 PSG Publishing Littleton 58
162. W.H. West K.W. Tauer J.R. Yannelli Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer N Engl J Med 316 1987 898
163. H.M. Yang R.A. Reisfeld Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma–associated proteoglycan suppresses the growth of established tumor xenografts in nude mice Proc Natl Acad Sci USA 85 1988 1189
164. H. Yoshizawa A.E. Chang S. Shu Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2 J Immunol 147 1991 729
165. R.M. Zinkernagel P.C. Doherty Restriction of in vitro T-cell–mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semi-allogeneic system Nature 248 1974 701